Advancing Cell Therapy Development With Integrated Analytical And Process Strategies

By Patrick Kellish, Ph.D., Senior Scientist, Analytical Development, Kincell Bio

Developing cell therapies requires aligning complex manufacturing parameters with critical quality attributes from the very beginning. Treating process and analytical method development as separate silos often leads to poorly characterized products, unexpected delays, and regulatory hurdles during IND and BLA submissions. Integrating these disciplines through a stage-gate, design-of-experiments approach provides actionable data that guides scale-up and de-risks commercialization. Incorporating advanced techniques like 3' RNA sequencing alongside modified flow cytometry panels allows teams to measure T-cell exhaustion, evaluate media formulations, and track phenotypic shifts with high precision. Making evidence-based decisions early ensures therapies maintain their target product profile while accelerating clinical timelines.

Read the full whitepaper to explore real-world case studies on CAR detection, T-cell subset assessment, and RNA-Seq workflows.